Clinical Trials · NCT06619015
Tailoring Obesity Treatment Trial
- Phase
- Phase 2/Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
- Enrollment
- 0
- Start date
- Apr 2025
- Locations
- 1 site, Denmark
- Primary endpoint
- Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 26 weeks of semaglutide of which the last two weeks is with the addition of either pramlintide or placebo